Figure 4.

Mean (SEM) percent of pre-dose baseline-normalized α₄β₇ receptor profiles on CD4+ naïve (A free, B total) and central memory (C free, D total) T cells after AMG 181 or placebo administration in healthy subjects. s.c. = subcutaneous; i.v. = intravenous. HV = healthy volunteers. , Cohort 1: 0.7 mg s.c. (n = 3–4); , Cohort 2: 2.1 mg s.c. (n = 4); , Cohort 3: 7.0 mg s.c. (n = 5–6); , Cohort 4: 21 mg s.c. (n = 5–6); , Cohort 5: 70 mg s.c. (n = 4–6); , Cohort 6: 210 mg s.c. (n = 4–6); , Cohort 7: 70 mg i.v. (n = 5–6); , Cohort 8: 210 mg i.v. (n = 4–6); , Cohort 9: 420 mg i.v. (n = 4–6); , placebo (n = 1–18)